The new docusate sodium stool softener expands the MiraLAX product line in the US.
Bayer announced on September 29, 2026, the launch of MiraSOFT, a new stool softener formulated with the active ingredient docusate sodium. The product is designed to relieve occasional constipation by gently softening dry stools to ease bowel movements.
The new digestive health offering is available immediately across more than 7,000 CVS Pharmacy retail locations in the digestive health aisle, as well as online at cvs.com.
MiraSOFT represents an important expansion of the Mira portfolio and reflects our commitment to bringing trusted digestive health solutions to consumers where they shop. Through our launch with CVS Pharmacy, we're making a gentle stool softener option from the makers of MiraLAX available to millions of shoppers seeking more comfortable bowel movements.
Tim Dolan, Interim Vice President of Consumer Health Care at CVS Health, stated that the retail chain is offering MiraSOFT exclusively to serve evolving customer demand in gut health.
In fiscal 2025, Bayer employed approximately 88,000 people globally and generated sales of 45.6 billion euros, alongside research and development expenses of 5.8 billion euros.
Newsletter
Markets in your inbox, weekly
Latin America-focused analysis, investment themes and the week in finance.
